cyclerion
therapeutics
reports
third
quarter
financial
results
recent
corporate
updates
positive
translational
pharmacology
study
healthy
elderly
subjects
showed
significant
improvements
multiple
measures
associated
cognitive
decline
neurodegenerative
diseases
company
revamping
organization
focus
critical
cns
program
priorities
expects
average
cash
use
reduction
approximately
levels
company
anticipates
current
cash
sufficient
fund
current
cns
priorities
including
melas
adv
studies
characterization
novel
pharmacology
melas
study
expected
initiate
readout
adv
study
expected
initiate
cambridge
globe
newswire
cyclerion
therapeutics
nasdaq
cycn
biopharmaceutical
company
developing
innovative
medicines
people
serious
diseases
central
nervous
system
cns
reported
financial
results
third
quarter
ended
september
provided
general
corporate
pipeline
updates
highly
encouraged
data
translational
pharmacology
study
showing
robust
consistent
positive
effects
multiple
measures
brain
neurophysiology
associated
cognitive
decline
neurodegenerative
diseases
said
peter
hecht
chief
executive
officer
cyclerion
promising
new
approach
cns
diseases
limited
therapeutic
options
today
building
exciting
translational
pharmacology
study
results
leveraging
team
neuroscience
expertise
company
concentrate
developing
meaningful
treatments
serious
cns
diseases
immediate
priority
rapidly
efficiently
assess
clinical
profile
look
forward
initiating
enrollment
melas
study
quarter
adv
study
recent
program
business
updates
program
update
cyclerion
announced
promising
results
phase
translational
pharmacology
study
first
soluble
guanylate
cyclase
sgc
stimulator
clinical
development
cns
disorders
treatment
crossover
study
confirmed
extended
results
seen
earlier
phase
study
daily
oral
treatment
demonstrated
penetration
desired
cns
exposure
levels
target
engagement
showed
safe
generally
study
subjects
receiving
showed
improvements
several
neurophysiological
objective
performance
measures
associated
cognitive
decline
neurodegenerative
diseases
effects
cerebral
blood
flow
markers
bioenergetics
observed
study
healthy
elderly
subjects
results
support
ongoing
development
serious
cns
diseases
cyclerion
expects
begin
enrolling
phase
clinical
trial
patients
mitochondrial
encephalomyopathy
lactic
acidosis
episodes
melas
quarter
company
use
findings
translational
pharmacology
study
addition
observations
previous
phase
study
healthy
subjects
inform
clinical
development
activities
including
initiation
planned
phase
clinical
trial
alzheimer
disease
vascular
pathology
adv
well
explore
potential
indications
july
company
announced
awarded
grant
alzheimer
association
part
partnership
grant
program
award
support
company
upcoming
phase
trial
adv
award
provides
cyclerion
million
funding
next
years
sickle
cell
program
update
company
announced
results
study
olinciguat
investigational
daily
vascular
sgc
stimulator
potential
treatment
sickle
cell
disease
scd
olinciguat
generally
well
tolerated
across
doses
results
demonstrate
adequate
activity
support
internal
clinical
development
cyclerion
intends
complete
analysis
study
results
present
publish
future
medical
forum
company
announced
results
study
olinciguat
investigational
daily
vascular
sgc
stimulator
potential
treatment
sickle
cell
disease
scd
olinciguat
generally
well
tolerated
across
doses
results
demonstrate
adequate
activity
support
internal
clinical
development
cyclerion
intends
complete
analysis
study
results
present
publish
future
medical
forum
praliciguat
update
company
working
rights
praliciguat
orally
administered
systemic
sgc
stimulator
expanded
discussions
beyond
treatment
cardiometabolic
disorders
include
additional
indications
sgc
stimulators
demonstrated
efficacy
company
working
rights
praliciguat
orally
administered
systemic
sgc
stimulator
expanded
discussions
beyond
treatment
cardiometabolic
disorders
include
additional
indications
sgc
stimulators
demonstrated
efficacy
financing
july
cyclerion
announced
private
equity
investment
million
september
company
entered
sales
agreement
jefferies
llc
respect
offering
atm
offering
allows
sale
shares
time
time
next
three
years
open
market
price
september
shares
issued
sold
atm
offering
july
cyclerion
announced
private
equity
investment
million
september
company
entered
sales
agreement
jefferies
llc
respect
offering
atm
offering
allows
sale
shares
time
time
next
three
years
open
market
price
september
shares
issued
sold
atm
offering
strategic
update
organization
restructuring
consistent
previously
announced
intent
focus
developing
treatments
serious
cns
diseases
cyclerion
investments
directed
fund
current
cns
priorities
including
upcoming
melas
study
planned
adv
study
characterization
pharmacology
company
revamp
organization
beginning
immediately
align
priorities
company
expects
take
aggregate
charge
costs
approximately
million
expected
incurred
primarily
realize
annual
cash
savings
approximately
million
company
also
intends
exit
current
laboratory
office
facilities
early
expects
annual
cash
savings
million
spending
reductions
expected
lower
company
average
quarterly
cash
use
level
approximately
million
company
anticipates
current
cash
sufficient
fund
current
cns
priorities
including
ongoing
melas
study
planned
adv
study
characterization
pharmacology
transition
president
chief
scientific
officer
mark
currie
cyclerion
president
chief
scientific
officer
cso
transition
year
end
become
senior
advisor
continue
assist
company
scientific
strategic
matters
related
development
cns
portfolio
andreas
busch
chief
innovation
officer
effective
immediately
assume
currie
cso
responsibilities
currie
continues
president
year
end
third
quarter
financial
results
cash
position
cash
cash
equivalents
restricted
cash
balance
september
approximately
million
compared
approximately
million
june
cash
cash
equivalents
restricted
cash
balance
september
approximately
million
compared
approximately
million
june
research
development
expenses
research
development
expenses
approximately
million
third
quarter
compared
approximately
million
third
quarter
decrease
approximately
million
driven
decrease
approximately
million
salaries
expenses
primarily
due
lower
average
headcount
decrease
approximately
million
facilities
operating
costs
allocated
research
development
primarily
reduced
lease
footprint
decrease
approximately
million
external
research
costs
primarily
related
completion
praliciguat
trials
prior
year
research
development
expenses
approximately
million
third
quarter
compared
approximately
million
third
quarter
decrease
approximately
million
driven
decrease
approximately
million
salaries
expenses
primarily
due
lower
average
headcount
decrease
approximately
million
facilities
operating
costs
allocated
research
development
primarily
reduced
lease
footprint
decrease
approximately
million
external
research
costs
primarily
related
completion
praliciguat
trials
prior
year
general
administrative
expenses
general
administrative
expenses
approximately
million
third
quarter
compared
approximately
million
third
quarter
increase
primarily
due
professional
fees
supporting
recent
financing
activities
partially
offset
net
decrease
operating
expenses
due
lower
average
headcount
general
administrative
expenses
approximately
million
third
quarter
compared
approximately
million
third
quarter
increase
primarily
due
professional
fees
supporting
recent
financing
activities
partially
offset
net
decrease
operating
expenses
due
lower
average
headcount
net
loss
net
loss
approximately
million
third
quarter
compared
million
third
quarter
first
sgc
stimulator
developed
symptomatic
potentially
disease
modifying
therapy
serious
cns
diseases
nitric
oxide
one
several
fundamental
neurotransmitters
yet
leveraged
full
cns
therapeutic
potential
stimulates
sgc
signaling
enzyme
responds
presence
enhance
body
natural
ability
produce
cyclic
guanosine
monophosphate
cgmp
important
signaling
molecule
impaired
signaling
pathway
believed
play
important
role
pathogenesis
neurodegenerative
diseases
critical
basic
neuronal
functions
agents
stimulate
sgc
produce
cgmp
may
compensate
deficient
signaling
cyclerion
therapeutics
cyclerion
therapeutics
biopharmaceutical
company
focused
discovering
developing
commercializing
innovative
medicines
people
serious
diseases
central
nervous
system
cns
cyclerion
lead
program
pioneering
sgc
stimulator
clinical
development
mitochondrial
encephalomyopathy
lactic
acidosis
episodes
melas
alzheimer
disease
vascular
pathology
adv
information
cyclerion
please
visit
https
follow
us
twitter
cyclerion
linkedin
company
cyclerion
forward
looking
statement
press
release
contains
statements
within
meaning
section
securities
act
amended
section
securities
exchange
act
amended
statements
based
current
beliefs
expectations
management
team
involve
risks
potential
changes
circumstances
assumptions
uncertainties
including
statements
results
conduct
clinical
trials
interpretation
data
clinical
trials
clinical
potential
molecules
anticipated
timing
planned
clinical
trials
future
business
focus
business
operations
cyclerion
future
financial
performance
expense
levels
may
cases
use
terms
predicts
believes
potential
continue
anticipates
estimates
expects
plans
intends
may
could
might
likely
words
convey
uncertainty
future
events
outcomes
identify
statements
statement
subject
risks
uncertainties
could
cause
actual
results
differ
materially
expressed
implied
statement
applicable
risks
uncertainties
include
risks
listed
heading
risk
factors
elsewhere
form
filed
march
cyclerion
subsequent
sec
filings
including
form
filed
may
august
november
investors
cautioned
place
undue
reliance
statements
statements
except
otherwise
noted
speak
date
press
release
cyclerion
undertakes
obligation
update
statements
except
required
law
investors
carlo
tanzi
kendall
investor
relations
ctanzi
